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Abstract 
Dystrophinopathy is the commonest form of muscular dystrophy and comprises clinically recognized 
forms, Duchenne dystrophy and Becker dystrophy. Mutations in the dystrophin gene which consist of 
large gene deletions (65%), duplications (5%) and point mutations (30%) are responsible for reducing 
the amount of functional dystrophin protein in skeletal muscle fi bres leading to fi bre destruction and 
disease. The aims of this study are to investigate the detection rate, types and distribution of large 
gene deletions in Malaysian dystrophinopathy patients using the multiplex polymerase chain reaction 
(MPCR). MPCR of 18 “hot-spot deletion” regions along the dystrophin gene was performed on DNA 
from 48 muscle biopsy-confi rmed cases of dystrophinopathy. A positive detection rate of 58% (28/48) 
was observed, where 84% (16/19) Indian, 35% (6/17) Chinese and 50% (6/12) Malay ethnic groups 
showed deletions in their dystrophin genes. The Malaysian Indians appear to have a higher prevalence 
for large gene deletions compared to the Chinese and Malays. Further analyses of 42 confi rmed 
positive cases (present 28 plus previous 14 cases) by MPCR showed the majority of deletions were 
in the mid-distal region of the dystrophin gene (81% in exons 45-60). The MPCR is a specifi c and 
sensitive method for confi rmation of gene deletions responsible for dystrophinopathy.
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INTRODUCTION
The commonest type of muscular dystrophy is 
dystrophinopathy that includes the clinically 
more severe form of Duchenne dystrophy (DD) 
and the less severe form, Becker dystrophy 
(BD).1 Mutations in the large dystrophin gene 
that consists of 79 exons, result in reduced or 
absent functional dystrophin protein in skeletal 
muscles, leading to varying clinical severity. 
About 65% of DD/BD cases are the result of 
large scale gene deletions2, while about 5% are 
due to duplications3, with the remaining 30% 
arising from point mutations.4  
 Sequencing the dystrophin gene is time 
consuming because of the complex organisation of 
the introns and exons that spans 2.4 million base 
pairs (Mbp). However, it is fortunate that many 
of the large gene deletions within the dystrophin 
gene can be detected in specifi c “hotspot areas” 
of the gene. These “hotspots” are clustered in 
two main regions - at the 5’ proximal portion of 
the gene (exons 1, 3, 4, 5, 8, 13, 19) and within 
the mid-distal region (exons 42 - 45, 47, 48, 50 
- 53, 60).2,5,6  DNA amplifi cation by the multiplex 
polymerase chain reaction (MPCR) can detect 
98% of the large scale deletions in the dystrophin 
gene.5  
 The MPCR differs from the standard PCR 
in that more than two primer sets are used to 
amplify different regions of target DNA in a 
single reaction. The advantage of MPCR is its 
rapidity as multiple target sequences are amplifi ed 
simultaneously. MPCR requires only a very 
small amount of DNA that can be extracted from 
chorionic villi, blood and muscle samples. 
 The main objective of this study is to determine 
the detection rate of large gene deletions in 
Malaysian DD/BD patients using an established 
in-house MPCR technique. In addition, the 
multiracial composition of the Malaysian 
population could possibly lend itself to studying 
racial differences in dystrophinopathy, if any. 
There are currently no published reports of 
molecular analysis of the dystrophin gene in the 
Malaysian population.
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METHODS
Patient samples and DNA extraction 
Forty-eight cases of dystrophinopathy confi rmed 
by muscle biopsy and dystrophin protein 
immunohistochemistry were studied using 
MPCR. DNA from these cases was extracted 
from 19 blood and 29 frozen muscle samples. 
Blood samples were collected in EDTA tubes 
and stored at -20oC for DNA extraction. Frozen 
muscle samples were retrieved from the archives 
of the Dept of Pathology, Faculty of Medicine, 
University of Malaya. From each frozen muscle 
sample, a small piece (3mm x 3mm) was cut out 
in a cold -20oC cryostat and care was taken to 
avoid external DNA contamination by changing 
new blades, forceps and autoclaved aluminium 
foils on the cutting board between samples. 
Archived muscle DNA were used for the 29 
cases because either no blood was available for 
DNA analysis or the DNA extracted from blood 
samples were in such poor condition that it did 
not allow for optimal DNA amplifi cation.  DNA 
was extracted from both muscle and blood using 
the proteinase K/phenol-chloroform extraction 
techniques. Extracted DNA was solubilised in 
water and stored at -70oC. Thus, a total of 48 
patient (19 Indians, 17 Chinese and 12 Malays) 
known cases of DD/BD were used to study the 
detection rate of dystrophinopathy using MPCR. 
Ethical consent was obtained from the patients 
or parents for molecular characterisation of the 
dystrophin gene. 
Multiplex polymerase chain reaction (MPCR)
MPCR was carried out using 25-50 ng/ml of 
extracted DNA. Primers sets for amplifi cation 
of the 18 exons were synthesized according to 
published sequences.2,5,6 The primers were divided 
into 4 groups (M1, M2, M3 and M4) for 4 separate 
MPCR assays to allow optimum visualization of 
the amplifi ed products that differed from each 
other by a small number of bases (Tables 1 - 4). 
Group M1 amplifi ed exons 42, 45, 48, 51, 52 
and 53; M2 exons 43, 44, 47, 50 and 60; M3 
exons 1, 3, 4, and 13 and M4 exons 8, 6 and 19, 
respectively. MPCR was carried out with initial 
denaturation at 94oC for 5 min followed by 20 
cycles of annealing at 94oC for 30 sec, annealing at 
60oC for 30 sec and extension at 72oC for 2 min. A 
fi nal extension of 10 min was carried out at 72oC. 
Amplifi ed MPCR products were electrophoresis 
in 2% agarose gels at 80 volts for 60 minutes. 
Appropriate positive DNA controls were included 
in every MPCR reaction and comprised DNA from 
a normal male and normal female.  A DNA blank 
where no DNA was added to the MPCR reaction 
mixture was also included in every MPCR to 
Table 1: Primer sequences used for the amplification of exons 42, 45, 48, 51, 52 and 53 
Group M1 consist of 6 primer sets; the exons are arranged according to their product size from the largest 
to the smallest (top to bottom) 
 Exon Products Forward primer (5’ to 3’) Reverse primer (3’ to 5’) 
  (bp) 
 48 506 TTG/AAT/ACA/TTG/GTT/AAA/TCC/CA CCT/GAA/TAA/AGT/CTT/CCT/TA
   A/CAT/G C/CAC/AC 
 51 388 GAA/ATT/GGC/TCT/TTA/GCT/TGT/GTT GGA/GAG/TAA/AGT/GAT/TGG/T 
   /TC GG/AAA/ATC
 45 307 CTT/TCT/TTG/CCA/GTA/CAA/CTG/CAT CAT/TCC/TAT/TAG/ATC/TGT/CG
   /GTG C/CCT/AC
 53 212 TTG/AAA/GAA/TTC/AGA/ATC/AGT/GG CTT/GGT/TTC/TGT/GAT/TTT/CTT
   G/ATG /TTG/GAT/TG
 42 155 CAC/ACT/GTC/CGT/GAA/GAA/ACG/AT TTA/GCACAG/AGG/TCA/GGA/G
   G/ATG CA/TTG/AG
 52 113 AAT/GCA/GGA/TTT/GGA/ACA/GAG/GC TTC/GAT/CCG/TAA/TGA/TTG/TT
   G/TCC C/TAG/CCT/C
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monitor for DNA contamination. 
 In order to study the types and distribution of 
deletions in the dystrophin gene in the different 
ethnic groups in Malaysia, an additional 14 
dystrophinopathy cases with previously confi rmed 
deletions were analyzed together with results from 
the above 28 positive MPCR cases. Results from 
the additional 14 cases were from previously 
characterized blood DNA samples in the 
Department of Molecular Medicine, University 
of Malaya. 
RESULTS
The MPCR optimized was both sensitive and 
specifi c for the confi rmation of deletions in the 
dystrophin gene. Gel electrophoresis results 
showed distinct amplifi ed MPCR products for 
the non-deleted gene sequences in controls and 
patients. (Figure 1; lanes 2 - 4 and lanes 7 - 9). In 
patients with gene deletions, no MPCR products 
for the respective deleted exon were observed 
(lanes 5 and 6). The DNA blanks did not show 
any MPCR products. Figure 1 shows the gel 
Table 2: Primer sequences used for the amplification of exons 43, 44, 47, 50 and 60  
 
Group M2 consist of 5 primer sets; the exons are arranged according to their product size from the largest 
to the smallest (top to bottom) 
 Exon Products Forward primer (5’ to 3’) Reverse primer (3’ to 5’) 
  (bp) 
 44 426 GTT/GTG/TGT/ACA/TCG/TAG/GTG/T TCC/ATC/ACC/CTT/CAG/AAC/CT
   GT/A G/ATC/T 
 43 357 GAA/CAT/GTC/AAA/GTC/ACT/GGA/C ATA/TAT/GTG/TTA/CCT/ACC/CT 
   TT/CAT/GG T/GTC/GGT/CC
 50 271 CAC/CAA/ATG/GAT/TAA/GAT/GTT/C TCT/CTC/TCA/CCC/AGT/CAT/CA
   AT/GAA/T C/TTC/ATA/G
 47 181 CGT/TGT/TGC/ATT/TGT/CTG/TTT/CA GTC/TAA/CCT/TTA/TCC/ACT/GG
   G/TTA/C A/GAT/TTG
 60 139 AGG/AGA/AAT/TGC/GCC/TCT/GAA/A CTG/CAG/AAG/CTT/CCA/TCT/G
   GA/GAA/CG GT/GTT/CAG/G
Table 3: Primer sequences used for the amplification of exons 1, 3, 4 and 13  
 
Group M3 consist of 6 primer sets; the exons are arranged according to their product size from the largest 
to the smallest (top to bottom)  
 Exon Products Forward primer (5’ to 3’) Reverse primer (3’ to 5’) 
  (bp) 
 1 535 GAA/GAT/CTA/GAC/AGT/GGA/TAC/A TTC/TCC/GAA/GGT/AAT/TGC/CT
   GTA/ACA/AAT/GCA/TG C/CCA/GAT/CTG/AGT/CC 
 3 410 TCA/TCC/ATC/ATC/TTC/GGC/AGA/TT CAG/GCG/GTA/GAG/TAT/GCC/A 
   A/A AA/TGA/AAA/TCA
 13 238 AAT/AGG/AGT/ACC/TGA/GAT/GTA/G CTG/ACC/TTA/AGT/TGT/TCT/TC 
   CA/GAA/AT C/AAA/GCA/G
 4 196 TTG/TCG/GTC/TCC/TGC/TGG/TCA/GT CAA/AGC/CCT/CAC/TCA/AAC/A
   G TG/AAG/C
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Table 4: Primer sequences used for the amplification of exons 6, 8 and 19  
 
Group M4 consist of 6 primer sets; the exons are arranged according to their product size 
from the largest to the smallest (top to bottom)
 Exon Products Forward primer (5’ to 3’) Reverse primer (3’ to 5’) 
  (bp) 
 19 459 TTC/TAC/CAC/ATC/CCA/TTT/TCT/TC GAT/GGC/AAA/AGT/GTT/GAG/A
   C/A AA/AAG/TC 
 8 360 GTC/CTT/TAC/ACA/CTT/TAC/CTG/TT GGC/CTC/ATT/CTC/ATG/TTC/TA 
   G/AG A/TTA/G
 6 202 CCA/CAT/GTA/GGT/CAA/AAA/TGT/A GTC/TCA/GTA/ATC/TTC/TTA/CC 
   AT/GAA T/ATG/ACT/ATG/G
Table 5:  Positive MPCR cases with detailed results of large gene deletions in the dystrophin gene in 
the Malaysian Indians, Chinese and Malays 
  Race
 
Hotspot regions Indian Chinese Malay  Total 
 n = 19 n = 13 n = 10  (n = 42) %
5’ proximal region 3 2 3 8 19
(exons 1, 3, 4, 6, 8, 13, 19)
  
Mid-distal region 
(exons 42, 43, 44. 45, 47, 48,  16 11 7 34 81
50, 51, 52, 53, 60)
 
Total 19 13 10 42 100
electrophoresis results after MPCR with M2 for 
the amplifi cation of exons 43, 44, 47, 50 and 60 
in the dystrophin gene. 
 Large-scale gene deletions were observed in 
58% (28/48) of the cases. Out of 19 Indian patients, 
16 (84%) were positive; 6 (35%) Chinese patients 
and 6 Malay patients (50%) were also positive 
for deletions in the dystrophin gene. Twenty cases 
(42%) showed no deletions.
 To study the types and distribution of the 
large scale deletions present in the different 
ethnic groups among Malaysians, results from 
the above 28 MPCR positive cases from this 
study were analysed together with a previous 
group of 14 MPCR positive cases. Results from 
the combined 42 MPCR positive cases showed 
19% (8/42) had deletions in the 5’- proximal 
region and 81% (34/42) showed deletions in the 
mid-distal 3’ end of the dystrophin gene (exons 
42-60) (Table 5). There is a higher frequency of 
deletions in the mid-distal region of the gene in 
all the three ethnic groups being present in 84% 
(16/19) of Malaysian Indians, 85% (11/13) of 
Chinese and 70% (7/10) of Malays studied. There 
were no deletions in exon 60. Figure 2 shows the 
distribution of gene deletions in the 18 exons in 
the dystrophin gene observed in the three ethnic 
groups.  
DISCUSSION
In this study, MPCR was used to detect large-scale 
gene deletions in 48 muscle biopsy-confi rmed 
cases of dystrophinopathy. A positive detection 
rate of 58% (28/48) in the 5’-proximal (exons 
1, 3, 4, 6, 8, 13, 19) and mid-distal (exons 42, 
43, 44, 45, 47, 48, 50, 51, 52, 53, 60) hotspot 
regions was observed. Twenty muscle biopsy 
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Figure 1. Gel electrophoresis results after MPCR with M2 for the amplifi cation of exons 43, 44, 47, 50 and 60 in 
the dystrophin gene.  
Lane 1: 100 bp molecular weight ladder; lane 2: DNA from a normal male showing no deletions (presence of 
exons 44 (426 bp), 43 (357 bp), 50 (271 bp), 47 (181 bp) and 60 (139 bp); lane 3: DNA from a normal female 
showing no deletions; lane 4: DNA from a DMD patient showing no deletions; lane 5: DNA from a DMD patient 
showing deletions of exons 44, 43, 50 and 47; lane 6: DNA from a DMD patient showing deletions of exons 44 
and 43; lanes 7 - 9: DNA from DMD patients showing no deletions; lane 10: DNA blank where no DNA was 
added to the MPCR reaction.
cases showed no deletions.  Positive detection 
rates reported in other studies using the MPCR 
showed a large variation ranging from 32% to 
88%. In Asia, namely Arab, Chinese, and North 
Indian populations, the rate was 63.4%, 59.4% 
and 70.2% respectively.7-9 A multinational study 
consisting Singaporean, Japanese and Vietnamese 
populations showed lower detection rates at 40%, 
51%, and 32%, respectively.10  However, this study 
did not use muscle biopsy confi rmed diagnosis 
of dystrophinopathy.
 Part of the reason for higher detection rates 
in some of the studies may be related to using 
a MPCR that includes more than the standard 
18 hotspot exons. In the North Indian and 
Arab studies7,8, the MPCR used included the 
amplifi cation of additional exons - exons 20, 25, 
and 28. In a Venezuelan study where only 14 
exons were studied, the detection rate reported 
was only 37 %.11 However, in a study of a cohort 
of Vietnamese patients, the detection rate was 
only 32.4% despite a full complement of exons 
being amplifi ed.10 The detection rate obtained in 
our study of 58 % was found to be similar to the 
rate of 59.4% found in a similar study performed 
on a Chinese population.9
 The frequency of MPCR-detectable large-scale 
deletions in Indians compared to non-Indians 
(Malay and Chinese) seems to be signifi cantly 
higher (p= 0.003).  Whether or not the Indian 
ethnic group has a true higher prevalence for 
large-scale gene deletions (as opposed to point 
and other mutations) needs to be confi rmed in a 
larger series. Singh et al. interestingly showed that 
73 % of Northern Indians had a higher prevalence 
for large-scale gene deletions in which 81.2 % 
of the deletions were found in the mid–distal 
region.7 The results from this study showed that the 
Malaysian Indian ethnic group are consistent with 
their fi ndings. It has to be pointed out however, 
that generally the incidence of dystrophinopathy 
does not vary among races.12 It has also been 
suggested that due to the genetic drift, some local 
DNA environments may have been formed in the 
wild–type dystrophin gene that has allowed this 
locus to be predisposed to a higher frequency of 
breakpoint deletions, and thus a higher incidence 
of the disease in certain populations.7
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 In most of the studies reported, about one 
third of the deletions clustered at the proximal 
hotspots, with the remainder were located in the 
mid-distal region. However, in our study, 81% of 
the deletions were found in the mid-distal region 
(Table 5). This observation was also reported in 
two other studies carried out in German13 and 
North Indian7 populations where deletions in 
the mid-distal region were 92.5 % and 81.8 %, 
respectively.
 This study shows that the majority of 
dystrophinopathies can be diagnosed by MPCR, 
hence this should be the fi rst line of investigation 
rather than the more invasive muscle biopsy. 
However, muscle biopsy still has a role to play in 
situations where MPCR is not available or showed 
a negative result. When sequencing of the whole 
dystrophin gene becomes more readily accessible 
and less expensive, the need for muscle biopsy 
should become even lesser unless dystrophin 
gene mutations has been excluded and other limb 
girdle muscular dystrophies are considered in the 
differential diagnosis.
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